Comparative Pharmacology
Head-to-head clinical analysis: DAYSEE versus GILDESS 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYSEE versus GILDESS 1 20.
DAYSEE vs GILDESS 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DAYSEE (estradiol/norethindrone acetate) is a combination hormonal contraceptive that suppresses gonadotropins (FSH and LH) via negative feedback of estrogen and progestin, thereby inhibiting ovulation. Norethindrone also increases cervical mucus viscosity and induces endometrial atrophy.
GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (GnRH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).
One active tablet (norgestimate 0.18 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo. Each cycle: 7 days placebo, then 21 days active.
One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 18-36 hours), supporting once-daily dosing for steady state within 5 days.
Ethinylestradiol: terminal half-life ~13-27 hours (mean 17 hours). Gestodene: terminal half-life ~12-15 hours. Steady-state reached within 5-7 days.
Renal 70% (metabolites), biliary/fecal 30% (parent drug and metabolites). No active drug excreted unchanged.
Renal (estradiol: ~40-50% as glucuronide and sulfate conjugates; gestodene: ~30-40% as metabolites) and fecal (estradiol: ~20-30%; gestodene: ~30-40%). Less than 1% excreted unchanged.
Category C
Category C
Oral Contraceptive
Oral Contraceptive